News | Breast Imaging | May 16, 2017

Seno Medical's Imagio Opto-Acoustic Breast Imaging System Proves Strong Predictor of Malignancy

Results presented at the American Roentgen Ray Society Annual Meeting

Seno Medical's Imagio Opto-Acoustic Breast Imaging System Proves Strong Predictor of Malignancy

May 16, 2017 — Seno Medical Instruments Inc. recently announced that is Imagio opto-acoustic (OA/US) breast imaging system results correlate with the histopathological findings of benign and malignant breast masses. These data were highlighted during an oral presentation at the American Roentgen Ray Society (ARRA) Annual Meeting, May 1-5 in New Orleans.

The basis for this presentation is the institutional review board (IRB)-approved Phase III pilot study, which was designed to determine the histopathologic basis of OA/US breast imaging and investigate its ability to differentiate benign and malignant masses. A total of 92 patients with 94 solid or complex cystic and solid breast masses assessed as Breast Imaging-Reporting and Data System (BI-RADS) 3, 4 or 5 on conventional diagnostic ultrasound (CDU) were imaged with OA/US. For each mass, five pre-determined OA features – three internal features and two external features – were evaluated. The three internal features (internal vessels, blush and hemoglobin) and two external features (boundary zone vessels and peripheral zone vessels) were scored and correlated with benign and malignant histopathology.

Mean OA scores were higher for malignant masses compared to benign masses for all individual internal and external features, as well as for combined internal and external OA features. Statistical analysis showed that these differences were highly statistically significant. External features were more predictive of malignancy than internal features, with greater differences in their means and 99 percent confidence intervals between benign and malignant masses.

"These data reinforce previous findings suggesting that opto-acoustic diagnostic imaging may improve our ability to differentiate between benign and malignant breast masses. This could help us decrease the number of unnecessary breast biopsies performed for benign findings, reducing patient anxiety, discomfort and healthcare cost," said Reni Butler, M.D., principal study investigator and assistant professor of radiology and biomedical imaging at Yale University School of Medicine. "Unlike previously investigated functional modalities, opto-acoustic imaging provides real-time anatomic and functional information without ionizing radiation or the need for IV contrast injection, making it a potentially safer and more convenient option for patients."

The Imagio OA/US breast imaging system was designed and is being studied to identify two functional hallmarks of cancer: the presence of abnormal blood vessels (tumor angiogenesis) and the relative reduction in oxygen content of blood that occurs in cancer compared to benign masses and normal tissues. The technology is the subject of a U.S. PMA filing with the U.S. Food and Drug Administration (FDA).

For more information: www.senomedical.com

Related Content

Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
SmartCurve technology, a revolutionary breast imaging technology designed specifically for the curvature of the female breast to provide every woman with a more comfortable and accurate mammogram.
News | Mammography | September 14, 2018
Solis Mammography declared September Breast Wellness Month a
breast screening
News | Clinical Trials | September 13, 2018
Fewer and fewer women die from breast cancer in recent years but, surprisingly, the decline is just as large in the a
Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.
Feature | Breast Imaging | September 07, 2018 | By JoAnn Pushkin
If you are confused about the conflicting advice surrounding mammography screening guidelines, welcome to the club.
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Check-Cap Announces Interim Results of European Study of C-Scan System Version 3
News | Colonoscopy Systems | September 04, 2018
Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an...
Brain Iron Levels May Predict Multiple Sclerosis Disabilities
News | Neuro Imaging | August 31, 2018
A new, highly accurate magnetic resonance imaging (MRI) technique can monitor iron levels in the brains of multiple...
Study Finds Multiple Sclerosis Drug Slows Brain Shrinkage

An NIH-funded clinical trial suggested that the anti-inflammatory drug ibudilast may slow brain shrinkage caused by progressive MS. Image courtesy of Robert J. Fox, M.D., Cleveland Clinic.

News | Neuro Imaging | August 30, 2018
August 30, 2018 — Results from a clinical...